Presented at #UnionConf2026:
In a phase 2 randomized trial, 10 new four-drug regimens that included ganfeborole, BTZ-043, or both were assessed in participants with rifampin-susceptible pulmonary tuberculosis. Two regimens showed promise for further study. Full PARADIGM4TB (UNITE4TB-01) trial results: https://t.co/urH575onnS
Editorial by NEJM Editor-in-Chief Eric J. Rubin, MD, PhD: Slightly Alive — Improving Antituberculosis Therapy https://t.co/ExkcO3kJ4F
@UnionConference
Zhang and colleagues report autoantibodies neutralizing interferon-α, -ω, and -β in a man who died from H7N7 influenza and mutations in the viral proteins that may facilitate adaptation to humans. Read the full report: https://t.co/ViWImV73Ni
【The Spectrum of Tuberculosis from Infection to Disease】
@HeartlandNTBC & @MayoClinicINFD
👉Really useful resource for all clinicians (PDF available online for FREE)!
👉https://t.co/YP5uOriirp
#TBIntensive#IDFellow#IDMedEd
The 2022 Lancet COPD Commission called for a shift in thinking about COPD from an end-stage disease to one with different types of risk factors and trajectories.
A new update reviews progress made in the take-up of the recommendations: https://t.co/Q15brYAUlQ
Multiple autoimmune labels. Could one immune defect connect them?
High-yield pearls from #ACR26:
WHEN TO SUSPECT
Early onset • multiorgan autoimmunity • refractory disease • enteropathy • lymphoproliferation • recurrent infections.
ADULTS COUNT
~25% of IEI patients first develop symptoms in adulthood. Autoimmunity may be the only clue; absent infections or family history does not exclude IEI.
RECOGNISE THE PATTERN → RECONSIDER THE DIAGNOSIS
• Sicca/nephritis + infections → APDS
• Autoimmunity + cytopenias/enteropathy → CTLA4/LRBA
• Arthritis + ILD/alveolar haemorrhage → COPA
• Behçet-like disease → HA20 or STAT1 GOF
GENETICS CAN REDIRECT THERAPY
APDS → leniolisib
CTLA4/LRBA → abatacept
STAT1 GOF → consider JAK inhibition
TEST BEYOND SMALL PANELS
Consider exome/genome + copy-number analysis; reanalyse negative results. Suspected somatic variants need adequate sequencing depth.
The next breakthrough may be a molecular diagnosis.
Credit: Prof Megan A. Cooper
#ACR26 #ACRambassador #Rheumatology #ClinicalImmunology #PrecisionMedicine
Original Article: Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity (phase 3 TRIUMPH-1 trial) https://t.co/kzuY57bUTX
Editorial: A Triple Incretin Agonist for Obesity, Osteoarthritis, and Sleep Apnea https://t.co/AiXLT7r80k
#Endocrinology#Rheumatology
In two replicate phase 3 trials involving patients with COPD who were receiving inhaled maintenance therapy, add-on tozorakimab resulted in a lower rate of moderate or severe exacerbations than placebo. Full results of the OBERON and TITANIA trials and Research Summary: https://t.co/xhHZUXKaCK
🧫🟢 ¿Por qué un hongo puede ser "susceptible" en el laboratorio 🔬, pero el paciente no mejora? 🏥🤔
📖 The Lancet Infectious Diseases explica por qué la concentración mínima inhibitoria (CMI) no predice por sí sola la respuesta clínica.
#Micología#Antifúngicos
🍄🧬 La respuesta depende de múltiples factores:
🔬 Especie fúngica
💊 Exposición al antifúngico
📍 Foco de infección
🦠 Biopelículas y persistencia
🛡️ Inmunidad del paciente
📊 Los autores proponen un algoritmo para investigar las discrepancias entre laboratorio y evolución clínica.
🩺🔍 ¿Qué hacer?
✅ Integrar datos clínicos y farmacocinéticos.
💊 Monitorizar el antifúngico cuando esté indicado.
🎯 Controlar el foco infeccioso.
💡 👇🏻 https://t.co/o3rMyisYvl
#Microbiología #InfeccionesFúngicas @SEMicrobiologia
📢Happy to share an editorial, just published in @ThoraxBMJ, on a post hoc analysis of the CLEAR trial (PMID: 42557060)!
To test or not to test: reassessing the need for drug response assessment before inhaled hypertonic saline https://t.co/osykWoNuli
New #IDSAGuidelines!
IDSA has released updated evidence-based recommendations on the prevention of invasive aspergillosis in adult solid organ transplant recipients: https://t.co/yYl8psAqN0
ERJ Open Research: Treatment of patients with bronchiectasis with hypertonic saline or carbocisteine does not significantly reduce sputum viscoelastic properties and biomarker levels or alter bacterial community composition https://t.co/Di0X9CfL3z
ERJ Open Research: CPA/ABPA overlap represents a distinct clinical phenotype in individuals with CPA associated with underlying airway disease, antifungal resistance and Th2-driven inflammation, with rising biomarkers linked to disease progression https://t.co/DnmaxXywNn
Breathe: Structural sequelae after TB underpin infectious PTLD: bacterial, fungal and non-TB mycobacterial. Complications are frequent yet under-diagnosed, worsening mortality and quality of life. https://t.co/VkBWdE1diC
Bronchiectasis is driven by dynamic host–microbiome interactions, not single pathogens. Integrating microbial and immune multi-omics can define actionable endotypes, enabling precision therapy and accelerating translation from discovery to clinical care. https://t.co/5pUYrIAwqa